What treatments work for cannabinoid hyperemesis syndrome in children and teens?
A systematic review of 14 studies found that benzodiazepines were the most commonly reported effective treatment for pediatric CHS, followed by topical capsaicin and haloperidol, while traditional antiemetics were frequently ineffective.
Quick Facts
What This Study Found
Benzodiazepines were the most frequently reported effective treatment for pediatric CHS, followed by topical capsaicin cream and haloperidol. Nine of 14 studies described IV fluid resuscitation and hot bathing as supportive measures. Seven cases reported that traditional antiemetics were ineffective for CHS. Treatment approaches were highly heterogeneous across studies.
Key Numbers
14 studies included; benzodiazepines most effective; topical capsaicin and haloperidol also effective; 9/14 studies used IV fluids and hot baths supportively; 7 cases reported traditional antiemetics ineffective
How They Did This
Systematic review searching PubMed, Scopus, CINAHL, Web of Science, and Cochrane Library. 14 studies met inclusion criteria describing management strategies for pediatric CHS.
Why This Research Matters
As adolescent marijuana use increases, pediatric CHS is becoming more common in emergency departments. Knowing that traditional antiemetics often fail while benzodiazepines and capsaicin may work can help clinicians avoid ineffective treatments and reach for appropriate alternatives faster.
The Bigger Picture
The failure of standard antiemetics in CHS highlights that its mechanism differs from ordinary nausea and vomiting. CHS appears to involve cannabinoid receptor desensitization and TRPV1 pathway dysfunction rather than the serotonin or dopamine pathways targeted by typical antiemetics.
What This Study Doesn't Tell Us
Only 14 studies, mostly case reports and small series. No randomized controlled trials. Heterogeneous treatment protocols prevent direct comparisons. Publication bias likely favors reporting successful treatments.
Questions This Raises
- ?What is the optimal first-line treatment protocol for pediatric CHS?
- ?Could TRPV1 agonists other than capsaicin be effective?
- ?Why do some patients respond to benzodiazepines while others need haloperidol?
Trust & Context
- Key Stat:
- Traditional antiemetics often ineffective
- Evidence Grade:
- Systematic review of available literature, but based mostly on case reports and small series without controlled studies.
- Study Age:
- Published in 2021; pediatric CHS management remains largely based on expert opinion and case data.
- Original Title:
- Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review.
- Published In:
- The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 26(4), 339-345 (2021)
- Database ID:
- RTHC-03453
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Why don't regular anti-nausea medications work for CHS?
CHS appears to involve different mechanisms than ordinary nausea. Standard antiemetics target serotonin or dopamine receptors, while CHS involves cannabinoid receptor dysfunction and TRPV1 pathways, which is why capsaicin (a TRPV1 agonist) can be effective.
What should parents know about CHS in teens?
Adolescents with severe cyclic vomiting and cannabis use may have CHS. The most important treatment is cannabis cessation, but in acute episodes, benzodiazepines, topical capsaicin, or haloperidol may be more effective than standard anti-nausea drugs.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-03453APA
Reinert, Justin P; Niyamugabo, O'Neill; Harmon, Kiersi S; Fenn, Norman E. (2021). Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review.. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 26(4), 339-345. https://doi.org/10.5863/1551-6776-26.4.339
MLA
Reinert, Justin P, et al. "Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review.." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2021. https://doi.org/10.5863/1551-6776-26.4.339
RethinkTHC
RethinkTHC Research Database. "Management of Pediatric Cannabinoid Hyperemesis Syndrome: A ..." RTHC-03453. Retrieved from https://rethinkthc.com/research/reinert-2021-management-of-pediatric-cannabinoid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.